Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim

Abstract

This study assessed the ability of recombinant human stem cell factor (rHuSCF) to mobilize stem cells in 44 patients who had failed a prior mobilization (CD34+ yield 0.5-1.9 × 106/kg BW) with filgrastim-alone or chemotherapy-plus-filgrastim. The same mobilization regimen was used with the addition of rHuSCF. In the filgrastim-alone group (n = 13), rHuSCF 20 μg/kg was started 3 days before filgrastim and continued for the duration of filgrastim. In the chemotherapy-plus-filgrastim group (n = 31), rHuSCF 20 μg/kg/day plus filgrastim 5-10 μg/kg/day were administered concurrently. Leukaphereses were continued to a maximum of four procedures or a target of ≥ 3 × 106 CD34+ cells/kg. In both groups..